Zealand Pharma Shares Plunge 32% After Obesity Drug Trial Disappoints

Zealand Pharma's stock suffered its worst single-day decline in years after Phase 2 trial results for petrelintide failed to meet Wall Street's weight-loss expectations. The 10.7% reduction at 42 weeks fell short of the anticipated 12-15% range needed to compete effectively with Eli Lilly and Novo Nordisk's rival treatments.

Analysts across major institutions including JPMorgan, UBS, and Barclays uniformly characterized the data as underwhelming. Cantor Fitzgerald responded by downgrading the stock, noting the absence of clear dose-response differentiation between treatment groups raises significant questions about Phase 3 potential.

While the trial technically met its primary endpoint with statistically significant results at 28 weeks, the market reaction reflects deeper concerns about commercial viability in the increasingly competitive obesity drug market. The partnership with Roche now faces heightened scrutiny as investors reassess the drug's competitive positioning.